Benzinga FDA Rejects Atara Biotherapeutics' Cell Therapy Again, Stock Sinks
Atara Biotherapeutics stock drops on FDA rejection of EBVALLO BLA for serious post-transplant complication. FDA raises new concerns. read more
Atara Biotherapeutics stock drops on FDA rejection of EBVALLO BLA for serious post-transplant complication. FDA raises new concerns. read more